This was a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count \<30,000/μL on two counts no sooner than 7 days apart in the 15 days before treatment begins. The dose-finding portion of the study was completed. Part B treatment dose was 400 mg twice daily.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Percentage of Participants Who Achieved 2 or More Consecutive Platelet Counts by Starting Dose Level and Overall
Timeframe: Up to 24 Weeks
Part B: Percentage of Participants Who Achieved Platelet Counts >=50,000/μL
Timeframe: Up to 24 Weeks
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Related Treatment-Emergent Adverse Events
Timeframe: From first dose of rilzabrutinib (Day 1) up to last dose + 1 (up to 294 days)
Part B: Number of Participants With Treatment-Emergent Adverse Events and Treatment Related Treatment-Emergent Adverse Events
Timeframe: From first dose of rilzabrutinib (Day 1) up to last dose + 1 (approximately 170 days)